Cristina Sensi

Dr. Cristina Sensi

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2026 in The Journal of Sexual Medicine
Verified
Journal Article
Open access
Andrea SansoneAndrea Sansone
Andrea Sansone
ECElena Colonnello
Elena Colonnello
MEMitchell D Efros
Mitchell D Efros
RZRalph M Zagha
Ralph M Zagha
HSHarvey Samowitz
Harvey Samowitz
Emmanuele A. JanniniEmmanuele A. Jannini
Emmanuele A. Jannini
Background: Erectile dysfunction (ED) impairs sexual function beyond erection itself, yet its effect on orgasmic intensity, measurable by the validated psychometric tool Orgasmometer, remains largely unexplored. Sildenafil oral film (OF) is a novel formulation offering rapid dissolution and flexible dosing (25-100 mg, including an intermediate 75 mg dose). Aim: To investigate the relationship between ED severity and orgasmic intensity, and to evaluate whether Sildenafil OF restores orgasmic intensity in men with ED. Methods: This secondary, exploratory analysis of orgasmic intensity was not prespecified and was performed post-hoc on a Phase III, multicenter, randomized, double-blind, flexible-dose, placebo-controlled trial conducted across 17 US centers (January–December 2024; NCT05490680). Heterosexual men with a ≥6-month ED diagnosis were randomized 3:1 to Sildenafil OF or placebo for 12 weeks. Outcomes were assessed at baseline and at weeks 2, 4, 8, and 12. Outcomes: Primary endpoints were the International Index of Erectile Function (IIEF) Erectile Function domain and Sexual Encounter Profile questions 2 and 3 (SEP2/SEP3). The secondary endpoint of interest was the Orgasmometer score, alongside the Erection Hardness Score (EHS) and all IIEF domains. Results: Of 488 randomized participants, 439 completed all visits (Sildenafil OF: n = 326; placebo: n = 113). Baseline Orgasmometer scores progressively declined with ED severity (P < .001). Sildenafil OF significantly improved Orgasmometer scores versus placebo at week 2 (+1.67, P < .001), with continued improvement through week 12. Linear mixed-effects models identified the composite erectile score (EHS, SEP2, SEP3) as the strongest predictor of orgasmic intensity (β = 1.05 ± 0.03, P < .001). A formal counterfactual mediation analysis showed that erectile improvement partially mediated the treatment effect (indirect effect 0.66, 95% CI, 0.26-1.18; proportion mediated ~43%, 95% CI, 21%-67%), with a significant direct effect persisting (0.86, 95% CI, 0.41-1.37). Clinical Implications: Because erectile improvement explained ~43% of the effect on orgasmic intensity, erectile measures alone may not fully capture treatment response; a single-item assessment of orgasmic intensity may therefore complement erectile evaluation in men with ED. Sildenafil OF represents an effective, patient-friendly option addressing both domains. Strengths and Limitations: Strengths include large sample size, rigorous randomized controlled trial design, and use of a validated measure. Limitations include restriction to heterosexual men, absence of a healthy control group, and post-hoc analysis. Conclusion: In men with ED, orgasmic intensity was progressively lower with increasing ED severity, and treatment with Sildenafil OF improved it substantially, but not exclusively, through improvements in erectile rigidity and maintenance. Orgasmic intensity is a clinically relevant, low-burden measure that may complement erectile assessment in men with ED.

26 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Valeria FrangioneValeria Frangione
Valeria Frangione
CSCristina Sensi
Cristina Sensi
MRMilko Radicioni
Milko Radicioni
FMfabio marra
fabio marra
AGAndrea Maria Giori
Andrea Maria Giori
Introduction: Lorazepam is a widely prescribed benzodiazepine available in multiple pharmaceutical formulations. A novel lorazepam orodispersible film (ODF) has been developed as an alternative dosage form designed to address administration challenges and enhance treatment adherence. Its pharmacokinetic profile, including the rate and extent of absorption, and its tolerability were evaluated in comparison with commercially available oral formulations in two bioequivalence studies. Methods: Two single-center, single-dose, open-label, randomized studies were conducted in healthy adults under fasting conditions. Study A was a three-way crossover pilot study comparing lorazepam 2.5 mg ODF (test, T) with film-coated tablets (Tavor®, reference 1, R1) and orodispersible tablets (Tavor® ORO, reference 2, R2). Study B was a two-way crossover pivotal study comparing T with R1. Treatments were separated by washout periods of ≥7 days. Pharmacokinetic parameters and point estimates (PEs), expressed as the ratios of least-squares geometric means (T/R1 and T/R2), were assessed. Results: In both studies, lorazepam pharmacokinetic profile was comparable across formulations, with similar Cmax and area under the curve (AUC) values. Peak concentrations were reached within 1–1.5 h for all treatments, and the elimination half-life was approximately 15–16 h. The 90% CIs for Cmax, AUC0–t, and AUC0–∞ for T versus R1 and R2 were within the 80–125% bioequivalence range. All treatments were well tolerated, with somnolence being the most frequent adverse event. Conclusions: Lorazepam 2.5 mg ODF demonstrated bioequivalence to both film-coated and orodispersible tablet formulations, with a comparable tolerability profile, supporting its potential as a convenient alternative formulation for lorazepam.